ResMed holds the cleaner structural position, with valuation as the main driver and growth adding further support. Edwards Lifesciences still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is currently leaning toward Edwards Lifesciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with ResMed, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
The result is anchored in valuation, but profitability also reinforces the same direction. The overall score gap is 10 points in favour of ResMed Inc..
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
This level of similarity points to a meaningful structural match, though not a tight one.
The match is driven mainly by revenue growth trajectory and investment intensity.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
The two profiles are relatively close, but the price setup still leans toward ResMed Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where EW and RMD each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 7.6 turns lower.
Growth still tilts materially toward Edwards Lifesciences Corporation, which stops the result from looking dominant across the whole profile.
Valuation settles the comparison, while pricing and growth keep the broader setup from looking fully aligned.
Break down the EW vs RMD comparison across all dimensions with the full interactive tool.
Explore how EW and RMD each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.